Henry Schein Medical has entered an agreement with Cerebral Assessment Systems (CAS) to distribute Cognivue, the first computerised cognitive assessment screening device that helps practitioners to monitor current brain health and also future reversible dementia.

Cleared by the US Food and Drug Administration (FDA), the device is designed to detect early signs of dementia caused by sleep disorders, infection, systemic illness, and mood disorders.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The fully automated solution, Cognivue, displays controlled visual stimuli on a computer screen, which enables practitioners conducting a quantitative analysis of brain health to derive a composite score of overall brain functional integrity.

The device helps summarise the results on an easily interpreted report that is stored in the cloud, while it also offers a single quantitative score of brain health, allowing physicians to identify potential issues and address them before they get worse.

Global Medical Group president Bridget Ross said: “Our team is committed to not only leveraging our strong distribution network to help healthcare professionals gain greater access to this innovative technology, but also working with forward-thinking leaders such as CAS to help practitioners focus on delivering high-quality patient care for dementia.”

“Our goal is to distribute the device to all the practitioners looking for a solution that makes the assessment of cognitive function as routine as having your blood pressure taken.”

Cognivue monitors and measures how the brain processes information and is customised based on the individual patient, calibrating levels of difficulty based on how well a patient’s brain is performing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It produces fast and accurate results of the patient’s visual and motor capabilities.

Cognivue creator Dr Charles Duffy said: “Routine measurement of cognitive function should be available to all patients in order to detect discrepancies in brain functionality and then act on them as soon as possible.

“With Henry Schein Medical, our goal is to distribute the device to all the practitioners looking for a solution that makes the assessment of cognitive function as routine as having your blood pressure taken.

“Although an early diagnosis does not solve the cure, minimising the toll dementia takes on patients, by addressing some of the potential causes associated with this condition, is the next best option.”